KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In Process
Ratios

CRISPR Therapeutics AG (CRSP) Receivables - Net (2016 - 2024)

CRISPR Therapeutics AG (CRSP) has disclosed Receivables - Net for 10 consecutive years, with $25.0 million as the latest value for Q4 2024.

  • Quarterly Receivables - Net fell 87.5% to $25.0 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $25.0 million through Dec 2024, down 87.5% year-over-year, with the annual reading at $25.0 million for FY2024, 87.5% down from the prior year.
  • Receivables - Net hit $25.0 million in Q4 2024 for CRISPR Therapeutics AG, down from $200.0 million in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $200.0 million in Q4 2023 to a low of $33000.0 in Q2 2020.
  • Historically, Receivables - Net has averaged $23.0 million across 5 years, with a median of $150000.0 in 2021.
  • Biggest five-year swings in Receivables - Net: plummeted 99.4% in 2021 and later soared 105960.61% in 2023.
  • Year by year, Receivables - Net stood at $144000.0 in 2020, then skyrocketed by 111.81% to $305000.0 in 2021, then tumbled by 83.93% to $49000.0 in 2022, then soared by 408063.27% to $200.0 million in 2023, then crashed by 87.5% to $25.0 million in 2024.
  • Business Quant data shows Receivables - Net for CRSP at $25.0 million in Q4 2024, $200.0 million in Q4 2023, and $70.0 million in Q2 2023.